<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02429037</url>
  </required_header>
  <id_info>
    <org_study_id>rAd-p53-J1002</org_study_id>
    <nct_id>NCT02429037</nct_id>
  </id_info>
  <brief_title>P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head and Neck Cancer</brief_title>
  <official_title>Recombinant Adenoviral Human p53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable, Locally Advanced Head and Neck Cancer - a Open-labeled Randomized Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen SiBiono GeneTech Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen SiBiono GeneTech Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to investigate the efficacy and safety of rAd-p53 gene
      combined with radio- and chemo-therapy vs. radio- and chemo- therapy only in treatment of
      unresectable, locally advanced head and neck cancer. This is a phase 2, open labeled, and
      active-controlled study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate benefits of rAd-p53) gene therapy combined with radio- and chemo-therapy in
      treatment of unresectable, locally advanced head and neck cancer, total of 60 patients with
      above condition will be randomly assigned to two groups: the experiment group (EG) and the
      control group (CG). The EG received multi-point injections of rAd-p53 into tumor on day 1, 8
      and 15 at a dose of 2 × 10^12 viral particles (VP) in a 21-days cycle. Both EG and CG were
      given radiotherapy at a total dose of 60 Gy and chemotherapy (Cisplatin 100 mg/m2 IV on days
      1 plus paclitaxel 30 mg/m2 IV on day 1, 8 and 15). The patients will be treated until disease
      progression, withdrawal from study, or untolerated adverse events. study endpoints are
      efficacy (Progression-free survival, overall survival) and safety variables.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>three years after starting treatment</time_frame>
    <description>Patients will be followed up until progression or death, withdrawal from study, or until data cut-off after 3 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>from starting study treatment until 30 days after the last study treatment</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>three years after starting study treatment</time_frame>
    <description>Patients will be followed up until death, withdrawal from study, or until data cut-off after 3 years.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>rAd-p53 plus radiation and chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rAd-p53 tumor injection combined with radio- and chemo-therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiation and chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>radiation combined with chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rAd-p53</intervention_name>
    <description>multi-point injections of rAd-p53 into tumor on day 1, 8 and 15 at a dose of 2 × 10^12 viral particles (VP) in a 21-days cycle.</description>
    <arm_group_label>rAd-p53 plus radiation and chemotherapy</arm_group_label>
    <other_name>p53 gene therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation</intervention_name>
    <description>radiation therapy will be given at a total dose of 60 Gy by 2.0 Gy/fraction, daily Monday-Friday for 6 weeks.</description>
    <arm_group_label>rAd-p53 plus radiation and chemotherapy</arm_group_label>
    <arm_group_label>radiation and chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 100 mg/m2 IV on days 1 plus paclitaxel 30 mg/m2 IV on day 1, 8 and 15</description>
    <arm_group_label>rAd-p53 plus radiation and chemotherapy</arm_group_label>
    <arm_group_label>radiation and chemotherapy</arm_group_label>
    <other_name>chemotherapy: cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. histopathologically diagnosed head and neck cancer;

          2. unresectable, locally advanced;

          3. 18 years or older;

          4. with an Eastern Cooperative Oncology Group (ECOG) score of 0-2;

          5. with normal tests of hemogram, blood coagulation, liver and kidney function; 6.signed
             the informed consent form.

        Exclusion Criteria:

          1. Serious blood coagulation disorder, bleeding tendency, platelet &lt; 6 * 1000000000/L;

          2. have serious heart, lung function abnormalities or severe diabetes patients;

          3. active infection;

          4. severe atherosclerosis;

          5. AIDS patients;

          6. serious thrombotic or embolic events within 6 months;

          7. renal insufficiency requiring hemodialysis or peritoneal dialysis;

          8. pregnant or lactating women;

          9. mental disorder or disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xia He, MD, PhD</last_name>
    <phone>86-13601458518</phone>
    <email>13601458515@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianfeng Wu, MD, PhD</last_name>
    <phone>86-13923853040</phone>
    <email>595864485@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jiangsu cancer hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xia He, MD, PhD</last_name>
      <phone>86-13601458518</phone>
      <email>13601458515@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Jianfeng Wu, MD, PhD</last_name>
      <phone>86-13923753040</phone>
      <email>595864485@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2015</study_first_submitted>
  <study_first_submitted_qc>April 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <last_update_submitted>April 23, 2015</last_update_submitted>
  <last_update_submitted_qc>April 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>p53</keyword>
  <keyword>gene therapy</keyword>
  <keyword>head and neck cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

